DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Sphingomyelinases and Liver Diseases
Sphingolipids (SLs) are critical components of membrane bilayers that play a crucial role in their physico-chemical properties. Ceramide is the prototype and most studied SL due to its role as a second messenger in the regulation of multiple signaling pathways and cellular processes. Ceramide is a heterogeneous lipid entity determined by the length of the fatty acyl chain linked to its carbon backbone sphingosine, which can be generated either by de novo synthesis from serine and palmitoyl-CoA in the endoplasmic reticulum or via sphingomyelin (SM) hydrolysis by sphingomyelinases (SMases). Unlike de novo synthesis, SMase-induced SM hydrolysis represents a rapid and transient mechanism of ceramide generation in specific intracellular sites that accounts for the diverse biological effects of ceramide. Several SMases have been described at the molecular level, which exhibit different pH requirements for activity: neutral, acid or alkaline. Among the SMases, the neutral (NSMase) and acid (ASMase) are the best characterized for their contribution to signaling pathways and role in diverse pathologies, including liver diseases. As part of a Special Issue (Phospholipases: From Structure to Biological Function), the present invited review summarizes the physiological functions of NSMase and ASMase and their role in chronic and metabolic liver diseases, of which the most relevant is nonalcoholic steatohepatitis and its progression to hepatocellular carcinoma, due to the association with the obesity and type 2 diabetes epidemic. A better understanding of the regulation and role of SMases in liver pathology may offer the opportunity for novel treatments of liver diseases, We acknowledge the support from grants SAF2017-85877R and PID2019-111669RB from Plan Nacional
de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional
(FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD
and Cirrhosis funded by NIAAA/NIH; and support from AGAUR of the Generalitat de Catalunya SGR-2017-1112,
European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced
Liver Injury Network, “ER stress-mitochondrial cholesterol axis in obesity-associated insulin resistance and
comorbidities”—Ayudas FUNDACION BBVA and the Red Nacional 2018-102799-T de Enfermedades Metabólicas
y Cáncer. Project 201916/31 Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis
2019 by Fundació Marato TV3., Peer reviewed